الفهرس 
PrematurityOnly 14 pages are availabe for public view
 |  | from | 187 |  |  |
| | | from | 187 | | |
Abstract
Summary
The HHHFNC has been used recently as a respiratory support for various purposes including apnea of prematurity, primary respiratory support in respiratory distress syndrome, CPAP weaning and post extubation.
Also, neonatal HFNC is increasingly being applied in other clinical areas including during neonatal transport and for initial delivery room stabilization of premature infants.
The aim of this study was to compare the efficacy and safety of the HHHFNC as a non-invasive respiratory support for the initial management of respiratory distress in preterm infants ≥ 30 weeks gestation with birth weight ≥ 1300 g on admission. And also, as a post extubation respiratory support of those were initially required endotracheal intubation and conventional mechanical ventilator after birth.
This study was a prospective and randomized controlled trial. It was conducted at our Tanta University NICU, on 60 preterm neonates, over one-year period. They were randomized to receive HHHFNC (Fisher & Paykel Optiflow System, Healthcare, Auckland, New Zealand), at either flow rate 3 or 6 L\min as an initial respiratory support (group I) and post extubation (group II).
Exclusion criteria: Preterm neonates of gestational age <30 weeks and of birth weight <1300 g. Preterm neonates with major congenital heart diseases, upper airway anomalies, lung hypoplasia and neuromuscular disorders.